NCT02236975已完成2 期
Prospective, Multi-center, Randomized First-in-man Trial Examining the Safety and Efficacy of BuMA Supreme eG (Electro Grafting) Based Biodegradable Polymer Sirolimus-eluting Stent and Resolute Integrity Zotarolimus-eluting Durable Polymer Stent in Patients With de Novo Coronary Artery Stenosis.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 168
- 试验地点
- 12
- 主要终点
- Late Lumen Loss
研究概览
简要总结
Prospective, multi-center, randomized 1:1, single blind trial using BuMA Supreme versus Resolute Integrity conducted in approximately 14 interventional cardiology centers in The Netherlands, Belgium, Spain and Portugal.
Clinical follow-up will occur at 1, 9 and 12 months post-stent implantation. All patients will undergo repeat angiography at 9 months follow-up. QCA assessment will be performed at baseline (pre- and post-procedure) and at 9 months follow-up.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The subject is at least 18 years of age.
- •Clinical evidence of ischemic heart disease and/or a positive territorial functional study.
- •Documented stable angina pectoris (Canadian Cardiovascular Society (CCS) Classification 1, 2, 3 or 4) or unstable angina pectoris with documented ischemia (Braunwald Class IB-C, IIB-C, or IIIB-C), or documented silent ischemia
- •The patient has a planned intervention of a single de-novo lesion in one or two separate major epicardial territories (LAD, LCX or RCA).
- •Diameter Stenosis≥50 and<100%.
- •The visually estimated target lesion must be able to be covered by a single BuMA Supreme stent or a single Resolute Integrity stent (for available sizes refer to tables 1 and 2, page 20 and 21).
- •The target lesion reference diameter must be visually estimated to be ≥2.5 mm and ≤4.5 mm in diameter.
- •Written informed consent.
- •The patient agrees to the follow-up visits including a 9 month angiographic follow-up.
- •Patient must have completed the follow-up phase of any previous study.
排除标准
- •Female of child bearing potential (age <50 years and last menstruation within the last 12 months). Subjects with age <50 who underwent tubal ligation, ovariectomy or hysterectomy can be included.
- •Evidence of ongoing acute myocardial infarction (AMI) in ECG and/or elevated cardiac biomarkers (according to local standard hospital practice) have not returned within normal limits at the time of procedure
- •Patient suffered from stroke/TIA during the last 6 months.
- •Platelet count <100,000 cells/mm3 or >400,000 cells/mm3, a WBC of <3,000 cells/mm3, or documented or suspected liver disease (including laboratory evidence of hepatitis)
- •Known renal insufficiency (e.g. serum creatinine >2.5mg/dL, or creatinine clearance ≤30 mL/min), or subject on dialysis, or acute kidney failure (as per physician judgment).
- •Patient undergoing planned surgery within 6 months with the necessity to stop DAPT.
- •Patient requiring oral anticoagulation (Coumadin, Novel Oral Anticoagulant (NOAC))
- •History of bleeding diathesis or coagulopathy
- •The patient is a recipient of a heart transplant
- •Known hypersensitivity or contraindication to aspirin, heparin, antiplatelet medication specified for use in the study, sirolimus, zotarolimus, or cobalt-chromium.
- •Other medical illness (e.g. cancer, stroke with neurological deficiency) or known history of substance abuse (alcohol, cocaine, heroin etc.) as per physician judgment that may cause non-compliance with the protocol or confound the data interpretation or is associated with a limited life expectancy
- •The patient is simultaneously participating in another investigational device or drug study
结局指标
主要结局
Late Lumen Loss
时间窗: Up to 9 month
The primary endpoint is in-stent Late Lumen Loss (LLL) at 9 months after stent implantation as assessed by off-line QCA.
次要结局
- Cinical endpoint(9 and 12 month)
- Angiographic endpoint(9 and 12 month)
- Clinical endpoint(9 and 12 month)
研究者
研究点 (12)
Loading locations...
相似试验
终止
3 期
D-PLEX 302: Efficacy and Safety of D-PLEX in the Prevention of Sternal Infection Post Cardiac SurgerySurgical Site InfectionSternal InfectionCardiac SurgeryNCT03558984PolyPid Ltd.2
已完成
不适用
Clinical Investigation of Safety and Performance of a Medical Device (ClearPlasma) for the Treatment of Patients With Acute Upper Gastrointestinal Hemorrhage.Acute Upper Gastrointestinal BleedingAcute Upper Gastrointestinal HemorrhageNCT04174989PlasFree Ltd.53
进行中（未招募）
不适用
LIBRE (Ligamys, Internal Bracing, REconstruction) Study: Comparing Three Surgery Techniques After an Acute ACL Rupture.Anterior Cruciate Ligament RuptureNCT03441295University Hospital, Antwerp95
招募中
3 期
Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema AttacksAcute Hereditary Angio EdemaNCT06361537Octapharma124
Unknown
不适用
Rotablation vs Intravascular Lithotripsy in Calcified Coronary LesionsCalcificationCoronary Artery DiseaseNCT04960319Medical Care Center Prof. Mathey, Prof. Schofer, Ltd.100